AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03860493 — intervention group
Intervention type: PROCEDURE
Intervention: Perfusion evaluation with indocyanine green
Description: 1. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs.
Study NCT03284580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic intervention
Description: An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
Study NCT03284580 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural plus kinesiotherapy intervention program
Description: An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
Study NCT03284580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control or conservative intervention
Description: A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
Study NCT00210951 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
Study NCT00594815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
Description: Immunochemotherapy
Study NCT04609462 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy
Description: Oxygen therapy by conventional nasal cannula / prongs, venturi mask, or mask with reservoir
Study NCT04609462 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: Breathing support with High-flow nasal cannula
Study NCT00742261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089
Description: Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
Study NCT03481686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients with injections of ESA
Description: Patients will perform ASE injections themselves or by their spouses
Study NCT04108637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: penicillin allergy assessment pathway
Description: Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction
Study NCT02232568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Study NCT00470275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT03656380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg
Description: Mepolizumab 300 mg subcutaneous injection
Study NCT03656380 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mepolizumab 100 mg
Description: Mepolizumab 100 mg subcutaneous injection
Study NCT03656380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Saline subcutaneous injection
Study NCT04287270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assesment
Description: Evaluations which explained in the arms section will be made as described.
Study NCT02829567 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Study NCT02519985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArcScan Insight 100 very high-frequency digital ultrasound
Description: The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
Study NCT02970903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalPAD
Description: VitalPAD prototype device
Study NCT02970903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional tools
Description: Paper based records, screenshots of monitors and therapy devices
Study NCT01551511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
Study NCT01551511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical step-up approach to the Namisol arm.
Study NCT03715049 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fraxel Laser Treatment
Description: The device to be used in this study is a FDA approved device \[510(k) approval\] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
Study NCT03993106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sEphB4-HSA
Description: sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
Study NCT01168037 — intervention group
Intervention type: DEVICE
Intervention: Endovascular aortic repair with branched/fenestrated stent-graft
Description: Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
Study NCT01168037 — intervention group
Intervention type: PROCEDURE
Intervention: Open Surgical Repair
Description: aortic replacement with revascularization of visceral arteries
Study NCT06090136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: 5 mg TPN171H tablets，single dose,oral
Study NCT00299390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
Study NCT03916900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
Study NCT03916900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment
Description: Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
Study NCT03034070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic performance 3D T1
Description: Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study.
Study NCT01580215 — intervention group
Intervention type: DEVICE
Intervention: Zephyr Endobronchial Valve (EBV)
Description: • Implantation of at least one Zephyr EBV following Chartis assessment
Study NCT05021068 — intervention group
Intervention type: OTHER
Intervention: Postural Assessment
Description: Spinal mouse measurement
Study NCT02125669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser treatment
Description: Pulsed dye laser 595nm
Study NCT02125669 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM-Treatment
Description: using the pulsed dye laser (PDL) laser without releasing a pulse
Study NCT00241189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Study NCT00241189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Study NCT02625909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL for 6 weeks
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
Study NCT02625909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL for 12 weeks
Description: Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
Study NCT03873792 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women
Description: Physician diagnoses a history of asthma or eczema or allergic rhinitis
Study NCT03739203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine supplied in capsules
Study NCT03739203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplied in capsules
Study NCT03739203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT as prescribed by the physician per standard of care in clinical practice.
Study NCT03739203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant Therapy (ADT)
Description: ADT as prescribed by the physician per standard of care in clinical practice.
Study NCT02367833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
Study NCT02367833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Contraceptive
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
Study NCT02367833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive Vaginal Ring
Description: The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
Study NCT04276948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAD3
Description: NAD3 is an over-the-counter dietary supplement available online to consumers.
Study NCT04276948 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NAD3
Description: NAD3 is an over-the-counter dietary supplement available online to consumers.
Study NCT02293317 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-001
Description: A recombinant epitope based universal vaccine against seasonal and pandemic influenza
Study NCT02293317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIV
Description: HA based seasonal influenza vaccine, for 2014/15 seson
Study NCT02293317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TIV
Description: HA based seasonal influenza vaccine, for 2014/15 seson
Study NCT02293317 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT02842489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left lateral tilt-down position
Description: patients will be positioned on their left side and at an angle of 20 degree
Study NCT02842489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: left lateral horizontal position
Description: patients will be horizontally positioned on their left side
Study NCT04730232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
Study NCT04730232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
Study NCT02389153 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: collaborative care CHD
Description: Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
Study NCT02389153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: collaborative care CHD
Description: Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
Study NCT04028401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide
Description: Application of 5% benzoyl peroxide during 5 days before the procedure
Study NCT00606437 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation with Fludarabine in UCB Transplants
Description: Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
Study NCT00782847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DiaNe consultation and support program
Description: the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
Study NCT04615052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: A 16 weeks parallel-group randomised controlled trial will be performed, in which covid-19 survivors patients will complete a telemonitored home-based exercise training program, 3 times per week. The training program will involve strength, aerobic, balance and flexibility exercises.
Study NCT03517397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Contingency Management
Description: Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
Study NCT02483962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatine capsule
Description: Gelatine capsules containing no active ingredients.
Study NCT02483962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venavine Intensive®
Description: Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
Study NCT01469377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied in capsules
Study NCT01469377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied in capsules.
Study NCT03346694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Island Dressing
Description: participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
Study NCT03346694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena Negative Pressure wound dressing
Description: participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
Study NCT03346694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border Post-Op Ag
Description: Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
Study NCT02668536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sunscreen
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
Study NCT02668536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Sunscreen
Description: Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
Study NCT02668536 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BNP
Description: Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
Study NCT02668536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNP
Description: Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
Study NCT03566485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV
Study NCT03566485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given by mouth
Study NCT03566485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Given by mouth
Study NCT04059159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected Catheter
Description: Patients will use the Connected Catheter to empty the bladder during the course of treatment.
Study NCT04957875 — intervention group
Intervention type: DEVICE
Intervention: emergency endoscopic therapy
Description: When cirrhotic patients presented with AVB to the emergency department, emergency physicians consulted gastroenterologists on duty to assess the patient for suitability for endoscopy, usually after initial stabilization. Performance of endoscopy and its timing was at the discretion of the gastroenterologist on call. Therapeutic endoscopy for AVB was performed within 24 hours after consultation by an experienced attending endoscopist, using standard forward-viewing upper gastrointestinal video endoscopes at individual centers. Written informed consent for endoscopy was obtained before each procedure. The standard of care at all hospitals was to administer a vasoactive agent and antibiotics upon the patient's presentation. Packed red blood cells were transfused at the discretion of the attending gastroenterologist.
Study NCT00566696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Miltenyi Biotec CliniMACS stem cell selection device
Study NCT00566696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
Study NCT00566696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioplex®
Description: Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.